uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Irritable Bowel syndrome: Principles and novel treatment options
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Gastroenterologi/Hellström)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Gastroenterologi/Hellström)
2011 (English)In: Drugs of the future, ISSN 0377-8282, E-ISSN 2013-0368, Vol. 36, no 9, 669-675 p.Article, review/survey (Refereed) Published
Abstract [en]

There is growing interest in the area of irritable bowel syndrome (IBS) in developing tools to separate various subgroups of this disease in order to identify potentially different pathogenetic mechanisms. From such work, the ultimate goal is tailored treatment for the various subtypes of the disease. Among major achievements in this research, the finding of increased gut permeability is of great interest and suggests a luminal factor as a cause of disease, which would be able to maintain low-grade inflammation. There are various treatment options and significant activity in developing drugs that have the capability to inhibit gut motility and increase luminal secretion. The development of analogues to gut peptide hormones, such as glucagon-like peptide 1, is of primary interest, as these drugs rarely give rise to inconvenient adverse reactions at therapeutic doses. Some of these drugs even exert their action directly on the luminal membranes, such as linaclotide, which means that oral administration is favored to diminish the risk of systemic reactions. The concept of IBS is anticipated to evolve into different disease mechanisms that will serve as the basis for customized treatments.

Place, publisher, year, edition, pages
2011. Vol. 36, no 9, 669-675 p.
National Category
Gastroenterology and Hepatology
Research subject
Medical Science
Identifiers
URN: urn:nbn:se:uu:diva-162872DOI: 10.1358/dof.2011.36.9.1665562ISI: 000296948700004OAI: oai:DiVA.org:uu-162872DiVA: diva2:461776
Available from: 2011-12-05 Created: 2011-12-05 Last updated: 2017-12-08Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textAbstract

Authority records BETA

Hellström, Per M.Webb, Dominic-Luc

Search in DiVA

By author/editor
Hellström, Per M.Webb, Dominic-Luc
By organisation
Department of Medical Sciences
In the same journal
Drugs of the future
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 420 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf